Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

hemotune

Explore full profile

Developing breakthrough blood purification technology, enabling revolutionary intervention strategies for the most urgent medical needs and making them accessible for the benefit of patients

Schlieren, SwitzerlandFounded 2017Biotech & Life Sciences
Valuation $50–100M Last recorded · 2024
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for hemotune and the history behind them.

About hemotune

Hemotune is a pioneering Swiss startup focused on revolutionizing the medical field with its advanced blood purification technology. The company has developed a groundbreaking medical device aimed at treating critically ill patients, particularly those suffering from septic shock—a severe and often fatal condition caused by an overwhelming immune response to infection. Hemotune's innovative approach combines biomedicine and nanotechnology to create a precision medicine treatment that uses magnetic beads to purify the blood and restore immune balance.

The primary clients for Hemotune's technology are hospitals and healthcare providers who treat critically ill patients. The market it operates in is the medical device and healthcare sector, with a specific focus on critical care and emergency medicine. Given the urgent need for effective treatments in these areas, Hemotune's technology has the potential to make a significant impact.

Hemotune's business model revolves around the development, production, and distribution of its blood purification devices. The company generates revenue by selling these devices to healthcare institutions and possibly through partnerships or licensing agreements with larger medical device companies. Additionally, Hemotune may explore opportunities for recurring revenue through maintenance contracts or consumable supplies related to their technology.

The company's mission is to make its revolutionary blood purification technology accessible to address the most urgent medical needs, ultimately improving patient outcomes and saving lives. Hemotune's interdisciplinary team of scientists, engineers, and clinicians is dedicated to bringing this breakthrough technology to clinical settings as quickly as possible.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Schlieren, Switzerland
Employees
32
Open positions
None listed
Dealroom signal
87.2/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Start-Up Rescue Instrument (EIT Health), Start-Up Rescue Instrument 2020 (EIT Health), EIT Health, Hard Tech
Technology
Hardware, Deep Tech
Business model
Manufacturing
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Mar 2024 $13M $51M ZKB - Zürcher Kantonalbank · EFI Lake Geneva Ventures · Belmondo Family Office · Hemex ↗
GRANTOther financing Apr 2023 $0 — Innosuisse ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

hemotune website traffic

Latest recorded traffic for hemotune is 240 monthly website visits, down 63.1% over the last three months. hemotune's team grew 3.2% over the past year.

Latest monthly visits240 3-month web change-63.1% 1-year team growth+3.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Venture Kick
  • European Innovation Council
  • Innosuisse

Series A7 investors entered at this stage

  • OCCIDENT
  • ZKB - Zürcher Kantonalbank
  • Greencross Medical Science Corp
  • VP Venture Partners
  • Hemex
  • Belmondo Family Office
  • EFI Lake Geneva Ventures

Other known investors3 additional known investors

  • EIT Health
  • ETH Zurich
  • VentureLab
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇭 Switzerland100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about hemotune on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See hemotune’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.